Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up – Still a Buy?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) gapped up before the market opened on Friday . The stock had previously closed at $12.45, but opened at $13.05. Adaptive Biotechnologies shares last traded at $12.9250, with a volume of 592,085 shares trading hands.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Recent fundamental backdrop: Adaptive’s Feb. 5 quarterly report showed an EPS beat and revenue that was up ~51% year-over-year, supporting investor confidence heading into March. MarketBeat ADPT profile
• Neutral Sentiment: Short-interest print for March shows 0 shares and NaN changes (likely a reporting error). That data point provides no clear bearish signal and may have contributed to lower perceived short pressure. (No reliable short-interest signal.)
• Negative Sentiment: Significant insider selling on Mar. 11–13: combined, company executives and insiders sold roughly 1.25M shares for about $16.6M in proceeds, materially reducing several insiders’ stakes (examples below). This coordinated selling can be perceived negatively by investors as supply into the market or insiders taking liquidity. Filings: CEO Chad M. Robins (470,167 sh, ~$6.19M) Chad Robins Form 4; Harlan S. Robins (470,266 sh, ~$6.19M) Harlan Robins Form 4; COO Julie Rubinstein (160,643 sh across filings) Julie Rubinstein Form 4; CFO Kyle Piskel (18,672 sh) Kyle Piskel Form 4; Sharon Benzeno (63,103 sh) Sharon Benzeno Form 4; Susan Bobulsky (41,338 sh) Susan Bobulsky Form 4; Francis Lo (30,593 sh) Francis Lo Form 4.

Analyst Upgrades and Downgrades

ADPT has been the subject of a number of research reports. JPMorgan Chase & Co. upped their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Morgan Stanley began coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price for the company. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Finally, Guggenheim lifted their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Adaptive Biotechnologies Price Performance

The stock has a market capitalization of $2.03 billion, a P/E ratio of -32.92 and a beta of 2.19. The stock has a 50 day moving average price of $16.55 and a 200-day moving average price of $15.87.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. During the same quarter in the previous year, the company posted ($0.23) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% on a year-over-year basis. Research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Insider Transactions at Adaptive Biotechnologies

In other news, insider Francis Lo sold 30,593 shares of the stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $14.08, for a total transaction of $430,749.44. Following the completion of the sale, the insider owned 291,374 shares of the company’s stock, valued at approximately $4,102,545.92. This represents a 9.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Kyle Piskel sold 18,672 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total transaction of $245,910.24. Following the completion of the transaction, the chief financial officer owned 259,840 shares in the company, valued at $3,422,092.80. This represents a 6.70% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 2,464,588 shares of company stock valued at $36,222,545. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in Adaptive Biotechnologies in the 2nd quarter worth approximately $793,000. SG Americas Securities LLC increased its stake in shares of Adaptive Biotechnologies by 53.2% during the second quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock valued at $435,000 after buying an additional 12,963 shares during the period. Allianz Asset Management GmbH increased its stake in shares of Adaptive Biotechnologies by 305.8% during the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock valued at $4,814,000 after buying an additional 242,474 shares during the period. Hillsdale Investment Management Inc. bought a new position in shares of Adaptive Biotechnologies during the second quarter valued at approximately $6,618,000. Finally, Envestnet Asset Management Inc. bought a new position in shares of Adaptive Biotechnologies during the second quarter valued at approximately $467,000. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.